Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23352546 | 1.00 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL17521211 | 1.00 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL29502677 | 1.00 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL21162582 | 1.00 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL9141685 | 1.00 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7512181 | 0.91 | PNP (0.61) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL7521688 | 0.89 | PNP (0.59) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL22036934 | 0.88 | CYP2C19 (0.53) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL8939245 | 0.88 | PNP (0.48) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23648144 | 0.88 | PNP (0.61) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601656-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2025-08-20 | — | — | EP | claimed |
| WO-2024077351-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2024-04-18 | — | — | WO | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| EP-3889602-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2021-10-06 | — | — | EP | claimed |
| US-20160355822-A1 | INHIBITORY OLIGONUCLEOTIDES AND THEIR USE IN THERAPY | SAREPTA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | claimed |
| US-20150344884-A1 | INHIBITORY OLIGONUCLEOTIDES AND THEIR USE IN THERAPY | SAREPTA THERAPEUTICS, INC. (US) | 2015-12-03 | — | — | US | claimed |
| EP-2943572-A1 | INHIBITORY OLIGONUCLEOTIDES AND THEIR USE IN THERAPY | Sarepta Therapeutics, Inc. (US) | 2015-11-18 | — | — | EP | claimed |
| WO-2014108529-A1 | INHIBITORY OLIGONUCLEOTIDES AND THEIR USE IN THERAPY | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-17 | — | — | WO | claimed |
| US-7871984-B2 | Methylated CpG polynucleotide | Sato, Yukio (JP) | 2011-01-18 | — | — | US | claimed |
| JP-5273209-A | — | — | None | — | — | JP | disclosed |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | APTAH BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | EDITAS MEDICINE, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| WO-2004048611-A2 | NUCLEIC ACID PROBES AND METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE COMPRISE TWO OR MORE CIS- LOCATED NUCLEIC ACID REGIONS | DYNAL BIOTECH LIMITED (GB) | 2004-06-10 | — | — | WO | disclosed |
| US-6495346-B1 | DO NOT REACT WITH FOREIGN PARTNERS; AMINO ACIDS INSERTED INTO PROTEINS WHICH NATURALLY FORM DIMERS, MUTATED PROTEINS ONLY FORM COMPLEXES WITH THEMSELVES (HOMODIMERS) OR WITH THE MUTATED PARTNER (HETERODIMERS), NOT WITH NONMUTATED STARTING | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-17 | — | — | US | disclosed |
| US-5412088-A | 6-O-substituted guanosine derivatives | RUTGERS, THE STATE UNIVERSITY (US) | 1995-05-02 | — | — | US | disclosed |
| JP-H05273209-A | DNA DETECTING KIT | TAKARA SHUZO CO LTD | 1993-10-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | UPF1, RPRD2, NR2E3 | PNP 1093/4885LMNA 718/4885TP53 3043/4885 |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | RPRD2, RTCB, UPF1 | PNP 205/4885LMNA 356/4885TP53 515/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | PNP 487/4885LMNA 3119/4885TP53 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.